MX356947B - Anticuerpos bioespecíficos específicos para antígenos que activan células t y un antígeno tumoral y métodos de uso. - Google Patents
Anticuerpos bioespecíficos específicos para antígenos que activan células t y un antígeno tumoral y métodos de uso.Info
- Publication number
- MX356947B MX356947B MX2014002097A MX2014002097A MX356947B MX 356947 B MX356947 B MX 356947B MX 2014002097 A MX2014002097 A MX 2014002097A MX 2014002097 A MX2014002097 A MX 2014002097A MX 356947 B MX356947 B MX 356947B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- tumor antigen
- cell activating
- bispecific antibodies
- antibodies specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a anticuerpos bisespecíficos que se enlazan específicamente a un antígeno activador de célula T y un antígeno de tumor (TA), que comprende un primer fragmento de Fab y un segundo fragmento de Fab, en donde ya sea una u otra de las regiones variables o las regiones constantes de las cadena pesada y cadena ligera del segundo Fab son intercambiadas y en donde el anticuerpo bisespecífico no comprende un dominio de Fc; métodos para su producción, composiciones farmacéuticas que contienen dichos anticuerpos y usos de los mismos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11178410 | 2011-08-23 | ||
PCT/EP2012/066226 WO2013026839A1 (en) | 2011-08-23 | 2012-08-21 | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014002097A MX2014002097A (es) | 2014-05-28 |
MX356947B true MX356947B (es) | 2018-06-20 |
Family
ID=46704675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014002097A MX356947B (es) | 2011-08-23 | 2012-08-21 | Anticuerpos bioespecíficos específicos para antígenos que activan células t y un antígeno tumoral y métodos de uso. |
Country Status (11)
Country | Link |
---|---|
US (2) | US20130058936A1 (es) |
EP (1) | EP2747781B1 (es) |
JP (2) | JP6159724B2 (es) |
KR (2) | KR101681818B1 (es) |
CN (2) | CN107586340B (es) |
BR (1) | BR112014004168A2 (es) |
CA (1) | CA2844540C (es) |
HK (1) | HK1249529A1 (es) |
MX (1) | MX356947B (es) |
RU (1) | RU2605390C2 (es) |
WO (1) | WO2013026839A1 (es) |
Families Citing this family (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
AR085403A1 (es) | 2011-02-28 | 2013-09-25 | Hoffmann La Roche | Proteinas monovalentes que se unen a antigenos |
WO2012116926A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Antigen binding proteins |
US20140161800A1 (en) | 2011-04-22 | 2014-06-12 | John W. Blankenship | Prostate-Specific Membrane Antigen Binding Proteins and Related Compositions and Methods |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
BR112014004166A2 (pt) * | 2011-08-23 | 2018-05-29 | Roche Glycart Ag | anticorpo biespecífico compreendendo pelo menos dois fragmentos fab, célula hospedeira procariótica ou eucariótica, metodo de produção de um anticorpo, imunoconjugado e invenção |
CN103890006A (zh) | 2011-08-23 | 2014-06-25 | 罗切格利卡特公司 | 抗mcsp抗体 |
CN107586340B (zh) | 2011-08-23 | 2022-01-21 | 罗切格利卡特公司 | 对t细胞活化性抗原和肿瘤抗原特异性的双特异性抗体及使用方法 |
KR20150029714A (ko) * | 2012-07-13 | 2015-03-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 이중특이적 항체의 공-도입에 의한 car 세포의 활성 증강 |
US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
US20150231241A1 (en) | 2012-08-14 | 2015-08-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
CA2874864C (en) | 2012-08-14 | 2023-02-21 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
KR20150064068A (ko) * | 2012-10-08 | 2015-06-10 | 로슈 글리카트 아게 | 2개의 Fab 단편을 포함하는 FC-부재 항체 및 이용 방법 |
TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
WO2014122144A1 (en) | 2013-02-05 | 2014-08-14 | Engmab Ag | BISPECIFIC ANTIBODIES AGAINST CD3ε AND BCMA |
MY192312A (en) | 2013-02-26 | 2022-08-17 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
CN105143270B (zh) | 2013-02-26 | 2019-11-12 | 罗切格利卡特公司 | 双特异性t细胞活化抗原结合分子 |
US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
EP2789630A1 (en) * | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
WO2015013671A1 (en) | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
ES2714708T3 (es) | 2013-10-01 | 2019-05-29 | Mayo Found Medical Education & Res | Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim |
CA2922912A1 (en) * | 2013-10-11 | 2015-04-16 | F. Hoffmann-La Roche Ag | Multispecific domain exchanged common variable light chain antibodies |
CN104560894B (zh) * | 2013-10-16 | 2017-07-14 | 北京中科永邦生物科技有限公司 | 编码分泌介导效应细胞杀伤靶细胞的双特异分子的框架及病毒 |
CN104707136A (zh) * | 2013-12-17 | 2015-06-17 | 江苏铼泰医药生物技术有限公司 | 新型双功能抗体偶联物及其制法和用途 |
TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
WO2015179654A1 (en) | 2014-05-22 | 2015-11-26 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti b7-h1 antibodies |
JP2017520575A (ja) | 2014-07-01 | 2017-07-27 | ファイザー・インク | 二重特異的ヘテロ二量体ダイアボディおよびその使用 |
MY181834A (en) | 2014-07-21 | 2021-01-08 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
AR101829A1 (es) | 2014-07-21 | 2017-01-18 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1 |
EP3171896A4 (en) | 2014-07-23 | 2018-03-21 | Mayo Foundation for Medical Education and Research | Targeting dna-pkcs and b7-h1 to treat cancer |
EP3172235A2 (en) | 2014-07-25 | 2017-05-31 | Cytomx Therapeutics Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
DK3608337T3 (da) | 2014-08-04 | 2024-06-17 | Hoffmann La Roche | Bispecifikke T-celleaktiverende antigenbindende molekyler |
EP2982692A1 (en) * | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
CA2963692A1 (en) * | 2014-10-09 | 2016-04-14 | Engmab Ag | Bispecific antibodies against cd3epsilon and ror1 |
KR102614189B1 (ko) | 2014-11-17 | 2023-12-18 | 리제너론 파아마슈티컬스, 인크. | Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법 |
PL3221355T3 (pl) | 2014-11-20 | 2021-03-08 | F. Hoffmann-La Roche Ag | Terapia skojarzona składająca się z dwuswoistych aktywujących limfocyty T cząsteczek wiążących antygen CD3 i receptor folianowy 1 (FolR1) oraz antagonistów wiązania osi PD-1 |
EP3029068A1 (en) * | 2014-12-03 | 2016-06-08 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases |
ES2923895T3 (es) * | 2015-02-27 | 2022-10-03 | Icell Gene Therapeutics Llc | Receptores de antígeno quimérico (CARS) dirigidos a neoplasisas malignas hematológicas, composiciones y métodos de uso de los mismos |
CA2981312C (en) | 2015-03-30 | 2023-09-26 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
WO2016164920A1 (en) * | 2015-04-09 | 2016-10-13 | Cornell University | Gene therapy to prevent reactions to allergens |
WO2016168769A1 (en) * | 2015-04-15 | 2016-10-20 | The California Institute For Biomedical Research | Chimeric receptor t cell switches for her2 |
EP3297673A4 (en) * | 2015-05-22 | 2019-05-08 | Memorial Sloan-Kettering Cancer Center | FOR A PRAME-PEPTIDE SPECIFIC T-CELL RECEPTOR-SIMILAR ANTIBODIES |
US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
CA2990177A1 (en) | 2015-06-25 | 2016-12-29 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
CN106467576B (zh) * | 2015-08-18 | 2020-04-07 | 中国科学院微生物研究所 | 一种抗体融合蛋白及其制备方法与应用 |
MY197562A (en) | 2015-09-21 | 2023-06-23 | Aptevo Res & Development Llc | Cd3 binding polypeptides |
EP3353212B1 (en) * | 2015-09-23 | 2021-11-03 | Regeneron Pharmaceuticals, Inc. | Optimized anti-cd3 bispecific antibodies and uses thereof |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
CR20180162A (es) | 2015-10-02 | 2018-05-25 | Hoffmann La Roche | Moléculas biespecíficas de unión a antígeno activadoras de células t |
MX2018003820A (es) * | 2015-10-02 | 2018-12-10 | F Hoffmann La Roche Ag | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador. |
WO2017075045A2 (en) * | 2015-10-30 | 2017-05-04 | Mayo Foundation For Medical Education And Research | Antibodies to b7-h1 |
CA2997406C (en) | 2015-12-09 | 2024-05-28 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release |
CN106661117B (zh) * | 2015-12-30 | 2020-11-17 | 深圳先进技术研究院 | IgG杂合型抗TNFα和IL-17A双特异性抗体 |
AU2017205089B2 (en) | 2016-01-08 | 2023-10-05 | F. Hoffmann-La Roche Ag | Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies |
AU2017209099A1 (en) | 2016-01-22 | 2018-08-02 | Janssen Biotech, Inc. | Anti-ROR1 antibodies, ROR1 x CD3 bispecific antibodies, and methods of using the same |
JP7438662B2 (ja) * | 2016-01-25 | 2024-02-27 | ジェネンテック, インコーポレイテッド | T細胞依存性二重特異的抗体をアッセイするための方法 |
DK3433280T3 (da) | 2016-03-22 | 2023-06-19 | Hoffmann La Roche | Protease-aktiverede T-celle-bispecifikke molekyler |
JP7010491B2 (ja) * | 2016-04-11 | 2022-01-26 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | ヒト化抗rage抗体 |
EA201892525A1 (ru) * | 2016-05-05 | 2019-04-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Конструкции днк-антител для применения против pseudomonas aeruginosa |
CA3029197A1 (en) | 2016-06-24 | 2017-12-28 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
JP7022123B2 (ja) | 2016-09-30 | 2022-02-17 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Cd3に対する二重特異性抗体 |
TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Car t細胞療法のための組成物および方法 |
SG11201909218RA (en) | 2017-04-03 | 2019-11-28 | Hoffmann La Roche | Antibodies binding to steap-1 |
CA3070272A1 (en) | 2017-07-20 | 2019-01-24 | Aptevo Research And Development Llc | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods |
TW201927816A (zh) | 2017-10-14 | 2019-07-16 | 美商Cytomx生物製藥公司 | 抗體、可活化之抗體、雙特異性抗體、和雙特異性可活化之抗體、及其使用方法 |
JP7357616B2 (ja) | 2017-12-05 | 2023-10-06 | 中外製薬株式会社 | Cd3およびcd137に結合する改変された抗体可変領域を含む抗原結合分子 |
BR112020011469A2 (pt) | 2017-12-21 | 2020-11-24 | F. Hoffmann-La Roche Ag | anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, uso do anticorpo, método de tratamento de uma doença e invenção |
EP3728309A2 (en) | 2017-12-22 | 2020-10-28 | Genentech, Inc. | Targeted integration of nucleic acids |
JP2021512147A (ja) | 2018-01-22 | 2021-05-13 | エンドサイト・インコーポレイテッドEndocyte, Inc. | Car t細胞の使用方法 |
EP3746480A1 (en) | 2018-01-31 | 2020-12-09 | F. Hoffmann-La Roche AG | Bispecific antibodies comprising an antigen-binding site binding to lag3 |
CN111630063A (zh) | 2018-01-31 | 2020-09-04 | 豪夫迈·罗氏有限公司 | 稳定化的免疫球蛋白结构域 |
US11866498B2 (en) | 2018-02-08 | 2024-01-09 | Genentech, Inc. | Bispecific antigen-binding molecules and methods of use |
TWI829667B (zh) | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | 結合gprc5d之抗體 |
WO2019166650A1 (en) | 2018-03-02 | 2019-09-06 | Cdr-Life Ag | Trispecific antigen binding proteins |
KR20200135510A (ko) | 2018-03-29 | 2020-12-02 | 제넨테크, 인크. | 포유류 세포들에서 젖분비자극 활성의 조절 |
AR115052A1 (es) | 2018-04-18 | 2020-11-25 | Hoffmann La Roche | Anticuerpos multiespecíficos y utilización de los mismos |
AU2019284911A1 (en) | 2018-06-13 | 2020-12-17 | Novartis Ag | BCMA chimeric antigen receptors and uses thereof |
CN112771077A (zh) | 2018-08-31 | 2021-05-07 | 瑞泽恩制药公司 | 针对cd3/c20双特异性抗体的减轻细胞因子释放综合征的给药策略 |
JPWO2020071554A1 (ja) * | 2018-10-05 | 2021-09-09 | 北海道公立大学法人 札幌医科大学 | がん幹細胞特異的抗体 |
SG11202103832SA (en) * | 2018-11-07 | 2021-05-28 | Crispr Therapeutics Ag | Anti-cd33 immune cell cancer therapy |
EP3980544A1 (en) | 2018-12-21 | 2022-04-13 | F. Hoffmann-La Roche AG | Targeted integration of nucleic acids |
MY194642A (en) | 2018-12-21 | 2022-12-09 | Hoffmann La Roche | Antibodies binding to cd3 |
CN113603783B (zh) * | 2018-12-21 | 2022-07-12 | 浙江时迈药业有限公司 | 蛋白酶可切割的双特异性抗体及其用途 |
CN111378045B (zh) * | 2018-12-28 | 2022-08-02 | 长春金赛药业有限责任公司 | 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物 |
CN112175087B (zh) * | 2019-07-02 | 2022-05-13 | 深圳市迈加瑞生物技术有限公司 | 一种抗CD4和TGFβ的双特异性抗体、其药物组合及其用途 |
JP2022543551A (ja) | 2019-07-31 | 2022-10-13 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Gprc5dに結合する抗体 |
PE20220394A1 (es) | 2019-07-31 | 2022-03-18 | Hoffmann La Roche | Anticuerpos que se fijan a gprc5d |
AU2020349509A1 (en) | 2019-09-18 | 2022-03-31 | Genentech, Inc. | Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use |
BR112022011854A2 (pt) | 2019-12-18 | 2022-09-06 | Hoffmann La Roche | Anticorpos, polinucleotídeo isolado, célula hospedeira, métodos para produzir um anticorpo e para tratar uma doença, composição farmacêutica, usos do anticorpo e invenção |
BR112022012439A2 (pt) | 2019-12-23 | 2022-09-06 | Genentech Inc | Anticorpos isolados, ácido nucleico isolado, vetor isolado, célula hospedeira isolada e métodos para produzir um anticorpo que se liga à apol1, para detectar apolipoproteína l1 em uma amostra, para distinguir apolipoproteína l1 endógena, para distinguir as formas g0 e g1 de apolipoproteína l1 da forma apol1 g2 e para detectar especificamente células de podócitos |
EP4106819A1 (en) | 2020-02-21 | 2022-12-28 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
CN115315512A (zh) | 2020-03-26 | 2022-11-08 | 基因泰克公司 | 具有降低的宿主细胞蛋白质的经修饰的哺乳动物细胞 |
CN115397866A (zh) | 2020-03-31 | 2022-11-25 | 中外制药株式会社 | 靶向dll3的多特异性抗原结合分子及其用途 |
WO2021214277A1 (en) | 2020-04-24 | 2021-10-28 | F. Hoffmann-La Roche Ag | Enzyme and pathway modulation with sulfhydryl compounds and their derivatives |
PE20240080A1 (es) | 2020-06-08 | 2024-01-16 | Hoffmann La Roche | Anticuerpos anti-hbv y metodos de uso |
WO2021255142A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 |
JP2023531625A (ja) | 2020-06-19 | 2023-07-25 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | CD3及びFolR1に結合する抗体 |
AU2021291011A1 (en) | 2020-06-19 | 2023-01-05 | F. Hoffmann-La Roche Ag | Antibodies binding to CD3 and CD19 |
WO2021255146A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and cea |
CN116096907A (zh) | 2020-06-24 | 2023-05-09 | 基因泰克公司 | 核酸的靶向整合 |
US20220041672A1 (en) | 2020-06-24 | 2022-02-10 | Genentech, Inc. | Apoptosis resistant cell lines |
CA3183993A1 (en) | 2020-07-01 | 2022-01-06 | Peter R. Baum | Anti-asgr1 antibody conjugates and uses thereof |
CN115776898A (zh) * | 2020-07-07 | 2023-03-10 | 百奥泰生物制药股份有限公司 | 双特异性抗体及其应用 |
PE20231300A1 (es) | 2020-07-17 | 2023-08-24 | Genentech Inc | Anticuerpos anti-notch2 y metodos de uso |
JPWO2022045247A1 (es) | 2020-08-27 | 2022-03-03 | ||
TW202227625A (zh) | 2020-08-28 | 2022-07-16 | 美商建南德克公司 | 宿主細胞蛋白質之CRISPR/Cas9多重剔除 |
CN116782955A (zh) * | 2020-10-18 | 2023-09-19 | 艾迪健公司 | 抗cspg4结合剂、其缀合物及其使用方法 |
EP4263609A1 (en) | 2020-12-17 | 2023-10-25 | F. Hoffmann-La Roche AG | Anti-hla-g antibodies and use thereof |
EP4288458A1 (en) | 2021-02-03 | 2023-12-13 | Genentech, Inc. | Multispecific binding protein degrader platform and methods of use |
WO2022192647A1 (en) | 2021-03-12 | 2022-09-15 | Genentech, Inc. | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use |
CA3215965A1 (en) | 2021-04-19 | 2022-10-27 | Amy Shen | Modified mammalian cells |
JP2024521107A (ja) | 2021-05-21 | 2024-05-28 | ジェネンテック, インコーポレイテッド | 目的の組換え産物を産生するための修飾細胞 |
KR20240032930A (ko) | 2021-07-13 | 2024-03-12 | 제넨테크, 인크. | 사이토카인 방출 증후군을 예측하기 위한 다변량 모델 |
EP4373859A1 (en) | 2021-07-22 | 2024-05-29 | F. Hoffmann-La Roche AG | Heterodimeric fc domain antibodies |
WO2023012147A1 (en) | 2021-08-03 | 2023-02-09 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use |
AR127887A1 (es) | 2021-12-10 | 2024-03-06 | Hoffmann La Roche | Anticuerpos que se unen a cd3 y plap |
US20230322958A1 (en) | 2022-01-19 | 2023-10-12 | Genentech, Inc. | Anti-Notch2 Antibodies and Conjugates and Methods of Use |
WO2024020564A1 (en) | 2022-07-22 | 2024-01-25 | Genentech, Inc. | Anti-steap1 antigen-binding molecules and uses thereof |
WO2024079015A1 (en) | 2022-10-10 | 2024-04-18 | F. Hoffmann-La Roche Ag | Combination therapy of a gprc5d tcb and imids |
WO2024079010A1 (en) | 2022-10-10 | 2024-04-18 | F. Hoffmann-La Roche Ag | Combination therapy of a gprc5d tcb and cd38 antibodies |
WO2024079009A1 (en) | 2022-10-10 | 2024-04-18 | F. Hoffmann-La Roche Ag | Combination therapy of a gprc5d tcb and proteasome inhibitors |
WO2024081918A1 (en) | 2022-10-14 | 2024-04-18 | Talem Therapeutics Llc | Anti-trkb/cd3 antibodies and uses thereof |
WO2024107879A1 (en) | 2022-11-15 | 2024-05-23 | Genentech, Inc. | Combined transposon-mediated integration and targeted integration of nucleic acids into host cells |
WO2024129594A1 (en) | 2022-12-12 | 2024-06-20 | Genentech, Inc. | Optimizing polypeptide sialic acid content |
Family Cites Families (185)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2388385B1 (fr) | 1977-04-18 | 1982-01-08 | Hitachi Metals Ltd | Piece d'ornement fixee par des aimants permanents |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
WO1991003493A1 (en) * | 1989-08-29 | 1991-03-21 | The University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
CA2129663C (en) | 1992-02-06 | 2005-07-05 | James S. Huston | Biosynthetic binding protein for cancer marker |
GB9221657D0 (en) | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant bispecific antibodies |
NZ258392A (en) | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5798100A (en) | 1994-07-06 | 1998-08-25 | Immunomedics, Inc. | Multi-stage cascade boosting vaccine |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
EP0831880A4 (en) | 1995-06-07 | 2004-12-01 | Imclone Systems Inc | ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US7423125B2 (en) | 1995-08-01 | 2008-09-09 | Vegenics Limited | Antibodies to VEGF-C |
DE69629580D1 (de) * | 1995-10-13 | 2003-09-25 | Us Gov Health & Human Serv | Immunotoxin enthaltend ein disulfid-stabilisiertes antikörperfragment |
DE69830901T2 (de) | 1997-05-02 | 2006-05-24 | Genentech Inc., San Francisco | ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
US6089968A (en) | 1997-05-28 | 2000-07-18 | Acraloc Corporation | Loin knife assembly for automatic loin puller apparatus |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
US20030060612A1 (en) | 1997-10-28 | 2003-03-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
DE69922159T2 (de) | 1998-01-23 | 2005-12-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Mehrzweck-antikörperderivate |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
DE60022369T2 (de) | 1999-10-04 | 2006-05-18 | Medicago Inc., Sainte Foy | Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
US20030180714A1 (en) | 1999-12-15 | 2003-09-25 | Genentech, Inc. | Shotgun scanning |
ATE344801T1 (de) | 1999-12-29 | 2006-11-15 | Immunogen Inc | Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung |
AU2001247616B2 (en) | 2000-04-11 | 2007-06-14 | Genentech, Inc. | Multivalent antibodies and uses therefor |
WO2002009573A2 (en) | 2000-07-31 | 2002-02-07 | The Brigham And Women's Hospital, Inc. | Prognostic classification of endometrial cancer |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US7041870B2 (en) | 2000-11-30 | 2006-05-09 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
EP1513879B1 (en) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
ES2408582T3 (es) * | 2003-05-30 | 2013-06-21 | Merus B.V. | Biblioteca de Fab para la preparación de una mezcla de anticuerpos |
NZ546173A (en) * | 2003-10-16 | 2009-04-30 | Micromet Ag | Multispecific deimmunized CD3-binders |
WO2005044859A2 (en) | 2003-11-05 | 2005-05-19 | Glycart Biotechnology Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
SI1725249T1 (sl) | 2003-11-06 | 2014-04-30 | Seattle Genetics, Inc. | Spojine monometilvalina, sposobne konjugacije na ligande |
US7235641B2 (en) * | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
AU2005230848B9 (en) | 2004-03-31 | 2011-06-02 | Genentech, Inc. | Humanized anti-TGF-beta antibodies |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
BRPI0511782B8 (pt) | 2004-06-03 | 2021-05-25 | Novimmune Sa | anticorpos anti-cd3, uso e método de produção dos mesmos, composição farmacêutica, molécula de ácido nucleico isolada e vetor |
WO2006034488A2 (en) | 2004-09-23 | 2006-03-30 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
AR052285A1 (es) | 2005-02-07 | 2007-03-07 | Glycart Biotechnology Ag | Moleculas de union al antigeno que fijan egfr, vectores que las codifican y usos de las mismas |
EP3623473A1 (en) | 2005-03-31 | 2020-03-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
AU2006232310B9 (en) * | 2005-04-06 | 2011-07-21 | Ibc Pharmaceuticals, Inc. | Improved stably tethered structures of defined compositions with multiple functions or binding specificities |
WO2006114115A1 (de) | 2005-04-26 | 2006-11-02 | Trion Pharma Gmbh | Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs |
EP1888649A2 (en) | 2005-05-09 | 2008-02-20 | GlycArt Biotechnology AG | Antigen binding molecules having modified fc regions and altered binding to fc receptors |
EP1910415A4 (en) * | 2005-07-25 | 2010-08-11 | Trubion Pharmaceuticals Inc | COMPOSITIONS AND PROCESSES FOR PROTEIN DEGREGATION |
US8008453B2 (en) * | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
BRPI0615026A8 (pt) | 2005-08-19 | 2018-03-06 | Abbott Lab | imunoglobulina de domínio variável duplo e seus usos |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
AU2006301492B2 (en) | 2005-10-11 | 2011-06-09 | Amgen Research (Munich) Gmbh | Compositions comprising cross-species-specific antibodies and uses thereof |
EP2465870A1 (en) | 2005-11-07 | 2012-06-20 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
KR101410521B1 (ko) * | 2005-12-16 | 2014-06-20 | 아이비씨 파마슈티컬스, 인코퍼레이티드 | 다가 면역글로불린-계 생동성 어셈블리들 |
PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
CA2651567A1 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
US20070274985A1 (en) | 2006-05-26 | 2007-11-29 | Stefan Dubel | Antibody |
MX2008015524A (es) | 2006-06-12 | 2009-01-13 | Trubion Pharmaceuticals Inc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
EP1900752A1 (en) * | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
PT2520590T (pt) | 2007-04-03 | 2018-11-14 | Amgen Res Munich Gmbh | Domínio de ligação específico de espécies cruzadas |
RS53008B2 (sr) | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
MX2009010611A (es) | 2007-04-03 | 2010-03-26 | Micromet Ag | Enlazadores biespecificos, especificos para especies. |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
CN101952312A (zh) * | 2007-07-31 | 2011-01-19 | 米迪缪尼有限公司 | 多特异性表位结合蛋白及其应用 |
JP5490714B2 (ja) | 2007-11-28 | 2014-05-14 | メディミューン,エルエルシー | タンパク質製剤 |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8227577B2 (en) * | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US8242247B2 (en) * | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
PE20100092A1 (es) * | 2008-06-03 | 2010-03-12 | Abbott Lab | Inmunoglobulina con dominio variable dual y usos de la misma |
AU2009293640A1 (en) | 2008-09-22 | 2010-03-25 | Calmune Corporation | Methods and vectors for display of 2G12 -derived domain exchanged antibodies |
CA2738565C (en) * | 2008-10-01 | 2023-10-10 | Micromet Ag | Cross-species-specific psmaxcd3 bispecific single chain antibody |
MX2011010159A (es) * | 2009-04-02 | 2011-10-17 | Roche Glycart Ag | Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla. |
JP5616428B2 (ja) | 2009-04-07 | 2014-10-29 | ロシュ グリクアート アクチェンゲゼルシャフト | 三価の二重特異性抗体 |
CN102361883A (zh) * | 2009-04-07 | 2012-02-22 | 罗氏格黎卡特股份公司 | 双特异性抗-ErbB-1/抗-c-Met抗体 |
CN102459346B (zh) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
EP2435473B1 (en) | 2009-05-27 | 2013-10-02 | F.Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
PE20121552A1 (es) | 2009-08-31 | 2012-11-26 | Roche Glycart Ag | Anticuerpos monoclonales anti cea humanizados de afinidad madura |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
ME02505B (me) | 2009-12-29 | 2017-02-20 | Aptevo Res & Development Llc | Heterodimerni vezujući proteini i njihove upotrebe |
AR080793A1 (es) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | Anticuerpos biespecificos |
EP2569337A1 (en) | 2010-05-14 | 2013-03-20 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
UA113712C2 (xx) | 2010-08-13 | 2017-02-27 | Антитіло до fap і способи його застосування | |
RS59589B1 (sr) | 2010-11-05 | 2019-12-31 | Zymeworks Inc | Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu |
CN103429737B (zh) | 2010-11-30 | 2020-07-14 | 中外制药株式会社 | 细胞毒诱导治疗剂 |
EP3075745B1 (en) | 2011-02-10 | 2018-09-05 | Roche Glycart AG | Mutant interleukin-2 polypeptides |
KR20160044598A (ko) | 2011-03-29 | 2016-04-25 | 로슈 글리카트 아게 | 항체 Fc 변이체 |
US20140170148A1 (en) | 2011-04-20 | 2014-06-19 | Genmab A/S | Bispecific antibodies against her2 |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
CN103842383B (zh) | 2011-05-16 | 2017-11-03 | 健能隆医药技术(上海)有限公司 | 多特异性fab融合蛋白及其使用方法 |
ME03440B (me) | 2011-05-21 | 2020-01-20 | Macrogenics Inc | Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3 |
CA2837975C (en) | 2011-08-23 | 2022-04-05 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
CN107586340B (zh) | 2011-08-23 | 2022-01-21 | 罗切格利卡特公司 | 对t细胞活化性抗原和肿瘤抗原特异性的双特异性抗体及使用方法 |
US20130078250A1 (en) | 2011-08-23 | 2013-03-28 | Oliver Ast | Bispecific t cell activating antigen binding molecules |
PL2748202T3 (pl) | 2011-08-23 | 2018-12-31 | Roche Glycart Ag | Dwuswoiste cząsteczki wiążące antygen |
BR112014004166A2 (pt) | 2011-08-23 | 2018-05-29 | Roche Glycart Ag | anticorpo biespecífico compreendendo pelo menos dois fragmentos fab, célula hospedeira procariótica ou eucariótica, metodo de produção de um anticorpo, imunoconjugado e invenção |
EP2578230A1 (en) | 2011-10-04 | 2013-04-10 | Trion Pharma Gmbh | Removal of Tumor Cells from Intraoperative Autologous Blood Salvage |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
DK2794905T3 (da) | 2011-12-20 | 2020-07-06 | Medimmune Llc | Modificerede polypeptider til bispecifikke antistofgrundstrukturer |
CA2861335A1 (en) | 2012-01-26 | 2013-08-01 | Ibc Pharmaceuticals, Inc. | Targeting interferon-lambda with antibodies potently enhances anti-tumor and anti-viral activities |
JP6363021B2 (ja) | 2012-02-03 | 2018-07-25 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 抗原をトランスフェクトされたt細胞を伴う二重特異性抗体分子及び医薬におけるそれらの使用 |
NZ772318A (en) | 2012-04-20 | 2023-06-30 | Merus Nv | Methods and means for the production of ig-like molecules |
CA2874721A1 (en) | 2012-05-30 | 2013-12-05 | Tomoyuki Igawa | Target tissue-specific antigen-binding molecule |
WO2014022540A1 (en) | 2012-08-02 | 2014-02-06 | Regeneron Pharmaceuticals, Inc. | Multivalent antigen-binding proteins |
WO2014023679A1 (en) | 2012-08-07 | 2014-02-13 | Roche Glycart Ag | Composition comprising two antibodies engineered to have reduced and increased effector function |
CA2874864C (en) | 2012-08-14 | 2023-02-21 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
KR20150064068A (ko) | 2012-10-08 | 2015-06-10 | 로슈 글리카트 아게 | 2개의 Fab 단편을 포함하는 FC-부재 항체 및 이용 방법 |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
WO2014110601A1 (en) | 2013-01-14 | 2014-07-17 | Xencor, Inc. | Novel heterodimeric proteins |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
WO2014122144A1 (en) | 2013-02-05 | 2014-08-14 | Engmab Ag | BISPECIFIC ANTIBODIES AGAINST CD3ε AND BCMA |
JO3529B1 (ar) | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
MY192312A (en) | 2013-02-26 | 2022-08-17 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
MX2015010843A (es) | 2013-02-26 | 2016-04-04 | Roche Glycart Ag | Moleculas biespecificas de union al antigeno que activan celulas t. |
CN105143270B (zh) | 2013-02-26 | 2019-11-12 | 罗切格利卡特公司 | 双特异性t细胞活化抗原结合分子 |
US10351626B2 (en) | 2013-03-14 | 2019-07-16 | The Scripps Research Institute | Targeting agent antibody conjugates and uses thereof |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
JP6541581B2 (ja) | 2013-03-15 | 2019-07-10 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | 低濃度抗体製剤 |
UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
AU2014273475A1 (en) | 2013-05-28 | 2015-11-19 | Numab Innovation Ag | Novel antibodies |
EP3049443A4 (en) | 2013-09-27 | 2017-04-05 | Immunomedics, Inc. | Anti-trop-2 antibody-drug conjugates and uses thereof |
ES2811923T3 (es) | 2013-12-17 | 2021-03-15 | Genentech Inc | Anticuerpos anti-CD3 y métodos de uso |
CN112353943A (zh) | 2013-12-17 | 2021-02-12 | 豪夫迈·罗氏有限公司 | 用pd-1轴结合拮抗剂和紫杉烷治疗癌症的方法 |
UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
DK3608337T3 (da) | 2014-08-04 | 2024-06-17 | Hoffmann La Roche | Bispecifikke T-celleaktiverende antigenbindende molekyler |
WO2016019969A1 (en) | 2014-08-08 | 2016-02-11 | Ludwig-Maximilians-Universität München | Subcutaneously administered bispecific antibodies for use in the treatment of cancer |
DK3186283T3 (da) | 2014-08-29 | 2020-03-02 | Hoffmann La Roche | Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1 |
WO2016036678A1 (en) | 2014-09-02 | 2016-03-10 | Medimmune, Llc | Formulations of bispecific antibodies |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
CA2963692A1 (en) | 2014-10-09 | 2016-04-14 | Engmab Ag | Bispecific antibodies against cd3epsilon and ror1 |
CA2963696A1 (en) | 2014-10-09 | 2016-04-14 | Engmab Ag | Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer |
EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
EA201791121A1 (ru) | 2014-11-20 | 2018-04-30 | Ф. Хоффманн-Ля Рош Аг | Активирующие т-клетки биспецифические антигенсвязывающие молекулы против folri и cd3 |
CN107207609B (zh) | 2014-11-20 | 2022-07-19 | 豪夫迈·罗氏有限公司 | 共同轻链和使用方法 |
EP3029068A1 (en) | 2014-12-03 | 2016-06-08 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases |
JP2018520642A (ja) | 2015-05-01 | 2018-08-02 | ジェネンテック, インコーポレイテッド | マスク抗cd3抗体及びその使用方法 |
RU2748943C2 (ru) | 2015-06-16 | 2021-06-02 | Дженентек, Инк. | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА И АНТИТЕЛА С СОЗРЕВШЕЙ АФФИННОСТЬЮ ПРОТИВ FcRH5 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
EA036975B1 (ru) | 2015-08-03 | 2021-01-21 | Энгмаб Сарл | Моноклональные антитела против bcma |
WO2017055391A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific t cell activating antigen binding molecules binding mesothelin and cd3 |
WO2017055318A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Cd33xcd3 bispecific t cell activating antigen binding molecules |
EP3913000A1 (en) | 2015-10-02 | 2021-11-24 | F. Hoffmann-La Roche AG | Bispecific anti-cd19xcd3 t cell activating antigen binding molecules |
CR20180162A (es) | 2015-10-02 | 2018-05-25 | Hoffmann La Roche | Moléculas biespecíficas de unión a antígeno activadoras de células t |
JP2018533930A (ja) | 2015-10-02 | 2018-11-22 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性t細胞活性化抗原結合分子 |
CA2997406C (en) | 2015-12-09 | 2024-05-28 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release |
-
2012
- 2012-08-21 CN CN201710974104.6A patent/CN107586340B/zh active Active
- 2012-08-21 KR KR1020147004340A patent/KR101681818B1/ko active IP Right Grant
- 2012-08-21 CA CA2844540A patent/CA2844540C/en not_active Expired - Fee Related
- 2012-08-21 CN CN201280050795.6A patent/CN103889452B/zh active Active
- 2012-08-21 BR BR112014004168A patent/BR112014004168A2/pt not_active Application Discontinuation
- 2012-08-21 RU RU2014109551/15A patent/RU2605390C2/ru not_active IP Right Cessation
- 2012-08-21 MX MX2014002097A patent/MX356947B/es active IP Right Grant
- 2012-08-21 WO PCT/EP2012/066226 patent/WO2013026839A1/en active Application Filing
- 2012-08-21 US US13/591,024 patent/US20130058936A1/en not_active Abandoned
- 2012-08-21 JP JP2014526472A patent/JP6159724B2/ja active Active
- 2012-08-21 EP EP12748490.5A patent/EP2747781B1/en active Active
- 2012-08-21 KR KR1020167032645A patent/KR101870555B1/ko active IP Right Grant
-
2014
- 2014-05-05 US US14/269,950 patent/US11639397B2/en active Active
- 2014-07-21 HK HK18108903.9A patent/HK1249529A1/zh unknown
-
2017
- 2017-03-07 JP JP2017042702A patent/JP2017137329A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20140041856A (ko) | 2014-04-04 |
JP6159724B2 (ja) | 2017-07-05 |
RU2605390C2 (ru) | 2016-12-20 |
US20150274845A1 (en) | 2015-10-01 |
CN107586340B (zh) | 2022-01-21 |
KR101870555B1 (ko) | 2018-06-22 |
WO2013026839A1 (en) | 2013-02-28 |
CN107586340A (zh) | 2018-01-16 |
CN103889452A (zh) | 2014-06-25 |
EP2747781A1 (en) | 2014-07-02 |
KR101681818B1 (ko) | 2016-12-01 |
MX2014002097A (es) | 2014-05-28 |
US20130058936A1 (en) | 2013-03-07 |
JP2014529600A (ja) | 2014-11-13 |
US11639397B2 (en) | 2023-05-02 |
BR112014004168A2 (pt) | 2017-12-12 |
CN103889452B (zh) | 2017-11-03 |
JP2017137329A (ja) | 2017-08-10 |
RU2014109551A (ru) | 2015-09-27 |
HK1249529A1 (zh) | 2018-11-02 |
CA2844540A1 (en) | 2013-02-28 |
CA2844540C (en) | 2018-10-16 |
KR20160138583A (ko) | 2016-12-05 |
EP2747781B1 (en) | 2017-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX356947B (es) | Anticuerpos bioespecíficos específicos para antígenos que activan células t y un antígeno tumoral y métodos de uso. | |
MX2014001799A (es) | Anticuerpos sin fc qie comprenden dos fragmentos fab y metodos de uso. | |
AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
MX2020010382A (es) | Anticuerpos biespecificos para pd1 y tim3. | |
NZ728749A (en) | Anti-pd-l1 antibodies | |
MX2015012059A (es) | Anticuerpos biespecificos tetravalentes. | |
EP3786183A3 (en) | Antigen binding constructs to cd3 | |
AU2010234031A8 (en) | Trivalent, bispecific antibodies | |
CA2886433C (en) | Human monoclonal anti-pd-l1 antibodies and methods of use | |
MX2020004410A (es) | Anticuerpos biespecificos con funciones efectoras reducidas. | |
MX369148B (es) | Agentes de unión kir3dl2. | |
MX341921B (es) | Proteinas de union a antigeno. | |
NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
MX2022008079A (es) | Anticuerpos contra determinantes de la superficie de s. aureus. | |
PE20160690A1 (es) | Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos | |
WO2014012085A3 (en) | Bispecific asymmetric heterodimers comprising anti-cd3 constructs | |
MX2013009362A (es) | Anticuerpo contra el csf-1r. | |
TN2014000107A1 (en) | Anti-aplhabetatcr antibody | |
EP2579895A4 (en) | ANTI-VEGF ANTIBODIES AND USES THEREOF | |
SG178886A1 (en) | Humanized anti-cdcp1 antibodies | |
NZ631098A (en) | Anti-hepcidin antibodies and uses thereof | |
EA202090303A3 (ru) | Композиции антител для лечения опухолей | |
NZ623840A (en) | Anti-cd134 (ox40) antibodies and uses thereof | |
UA110789C2 (uk) | Антитіло, реактивне відносно b7-h3, його імунологічно активні фрагменти та їх застосування |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |